Anti-programmed cell death-1 antibody as a new serological marker for type 1 autoimmune hepatitis

Journal of Gastroenterology and Hepatology (Australia)

Volumn 29, Issue 1, 2014, Pages 110-115

  Matsumoto, Kazuyuki ^a   Miyake, Yasuhiro ^a   Matsushita, Hiroshi ^a   Ohnishi, Atsuyuki ^a   Ikeda, Fusao ^a   Shiraha, Hidenori ^a   Takaki, Akinobu ^a   Nouso, Kazuhiro ^a   Yamamoto, Kazuhide ^a  

^a OKAYAMA UNIVERSITY   (Japan)

Author keywords

Acute viral hepatitis; Autoimmune hepatitis; Drug induced liver injury; Primary sclerosing cholangitis; Programmed cell death 1

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIBODY; BILIRUBIN; IMMUNOGLOBULIN; PREDNISOLONE; PROGRAMMED DEATH 1 ANTIBODY; PROGRAMMED DEATH 1 RECEPTOR; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; APOPTOSIS; ARTICLE; AUTOIMMUNE HEPATITIS; BILIRUBIN BLOOD LEVEL; CONTROLLED STUDY; DISEASE MARKER; FEMALE; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PATHOGENESIS; PREVALENCE; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEROLOGY; TOXIC HEPATITIS; TREATMENT RESPONSE; VERY ELDERLY; VIRUS HEPATITIS; YOUNG ADULT;

ACUTE VIRAL HEPATITIS; AUTOIMMUNE HEPATITIS; DRUG-INDUCED LIVER INJURY; PRIMARY SCLEROSING CHOLANGITIS; PROGRAMMED CELL DEATH-1;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AUTOANTIBODIES; BIOLOGICAL MARKERS; DIAGNOSIS, DIFFERENTIAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; HEPATITIS, AUTOIMMUNE; HUMANS; LYMPHOCYTES; MALE; MIDDLE AGED; PROGRAMMED CELL DEATH 1 RECEPTOR; YOUNG ADULT;

EID: 84897584800     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.12340     Document Type: Article

References (29)

1. Krawitt EL. Autoimmune hepatitis. N. Engl. J. Med. 2006; 354: 54-66.
2. Alvarez F, Berg PA, Bianchi FB etal. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J. Hepatol. 1999; 31: 929-938.
3. Hennes EM, Zeniya M, Czaja AJ etal. International Autoimmune Hepatitis Group. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology 2008; 48: 169-176.
4. Kido M, Watanabe N, Okazaki T etal. Fatal autoimmune hepatitis induced by concurrent loss of naturally arising regulatory T cells and PD-1-mediated signaling. Gastroenterology 2008; 135: 1333-1343.
5. Topalian SL, Hodi FS, Brahmer JR etal. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 2012; 366: 2443-2454.
6. Serriari NE, Gondois-Rey F, Guillaume Y etal. B and T lymphocyte attenuator is highly expressed on CMV-specific T cells during infection and regulates their function. J. Immunol. 2010; 185: 3140-3148.
7. Takikawa H, Onji M. A proposal of the diagnostic scale of drug-induced liver injury. Hepatol. Res. 2005; 32: 250-251.
8. Takikawa H, Murata Y, Horiike N, Fukui H, Onji M. Drug-induced liver injury in Japan: an analysis of 1676 cases between 1997 and 2006. Hepatol. Res. 2009; 39: 427-431.
9. Chapman R, Fevery J, Kalloo A etal. American Association for the Study of Liver Diseases. Diagnosis and management of primary sclerosing cholangitis. Hepatology 2010; 51: 660-678.
10. Miyake Y, Iwasaki Y, Terada R etal. Persistent normalization of serum alanine aminotransferase levels improves the prognosis of type 1 autoimmune hepatitis. J. Hepatol. 2005; 43: 951-957.
11. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 1994; 19: 1513-1520.
12. Lüth S, Herkel J, Kanzler S etal. Serologic markers compared with liver biopsy for monitoring disease activity in autoimmune hepatitis. J. Clin. Gastroenterol. 2008; 42: 926-930.
13. Gregorio GV, McFarlane B, Bracken P, Vergani D, Mieli-Vergani G. Organ and non-organ specific autoantibody titres and IgG levels as markers of disease activity: a longitudinal study in childhood autoimmune liver disease. Autoimmunity 2002; 35: 515-519.
14. Montano-Loza AJ, Carpenter HA, Czaja AJ. Improving the end point of corticosteroid therapy in type 1 autoimmune hepatitis to reduce the frequency of relapse. Am. J. Gastroenterol. 2007; 102: 1005-1012.
15. Montano-Loza AJ, Mason AL, Ma M, Bastiampillai RJ, Bain VG, Tandon P. Risk factors for recurrence of autoimmune hepatitis after liver transplantation. Liver Transpl. 2009; 15: 1254-1261.
16. Yoshizawa K, Matsumoto A, Ichijo T etal. Long-term outcome of japanese patients with type 1 autoimmune hepatitis. Hepatology 2012; 56: 668-676.
17. Czaja AJ. Comparability of probable and definite autoimmune hepatitis by international diagnostic scoring criteria. Gastroenterology 2011; 140: 1472-1480.
18. Yeoman AD, Westbrook RH, Al-Chalabi T etal. Diagnostic value and utility of the simplified International Autoimmune Hepatitis Group (IAIHG) criteria in acute and chronic liver disease. Hepatology 2009; 50: 538-545.
19. Abe M, Mashiba T, Zeniya M, Yamamoto K, Onji M, Tsubouchi H, Autoimmune Hepatitis Study Group-Subgroup of the Intractable Hepato-Biliary Disease Study Group in Japan. Present status of autoimmune hepatitis in Japan: a nationwide survey. J. Gastroenterol. 2011; 46: 1136-1141.
20. Abe M, Onji M, Kawai-Ninomiya K etal. Clinicopathologic features of the severe form of acute type 1 autoimmune hepatitis. Clin. Gastroenterol. Hepatol. 2007; 5: 255-258.
21. Liang KP, Kremers HM, Crowson CS etal. Autoantibodies and the risk of cardiovascular events. J. Rheumatol. 2009; 36: 2462-2469.
22. Hayashi N, Koshiba M, Nishimura K etal. Prevalence of disease-specific antinuclear antibodies in general population: estimates from annual physical examinations of residents of a small town over a 5-year period. Mod. Rheumatol. 2008; 18: 153-160.
23. Longhi MS, Ma Y, Mitry RR etal. Effect of CD4+ CD25+ regulatory T-cells on CD8 T-cell function in patients with autoimmune hepatitis. J. Autoimmun. 2005; 25: 63-71.
24. Longhi MS, Hussain MJ, Mitry RR etal. Functional study of CD4+CD25+ regulatory T cells in health and autoimmune hepatitis. J. Immunol. 2006; 176: 4484-4491.
25. Ferri S, Longhi MS, De Molo C etal. A multifaceted imbalance of T cells with regulatory function characterizes type 1 autoimmune hepatitis. Hepatology 2010; 52: 999-1007.
26. Velu V, Titanji K, Zhu B etal. Enhancing SIV-specific immunity in vivo by PD-1 blockade. Nature 2009; 458: 206-210.
27. McGee HS, Yagita H, Shao Z, Agrawal DK. Programmed Death-1 antibody blocks therapeutic effects of T-regulatory cells in cockroach antigen-induced allergic asthma. Am. J. Respir. Cell Mol. Biol. 2010; 43: 432-442.
28. Rosenblatt J, Glotzbecker B, Mills H etal. PD-1 blockade by CT-011, anti-PD-1 antibody, enhances ex vivo T-cell responses to autologous dendritic cell/myeloma fusion vaccine. J. Immunother. 2011; 34: 409-418.
29. Wafula PO, Teles A, Schumacher A etal. PD-1 but not CTLA-4 blockage abrogates the protective effect of regulatory T cells in a pregnancy murine model. Am. J. Reprod. Immunol. 2009; 62: 283-292.